Sector News

Clinical trials firm BioClinica explores sale: sources

May 27, 2016
Life sciences

BioClinica Inc, a U.S. pharmaceutical contract research organization owned by buyout firm JLL Partners, is exploring a sale that could value it at as much as $1.3 billion, including debt, according to people familiar with the matter.

The Newtown, Pennsylvania-based company has hired investment bank Jefferies LLC to run an auction for the company, the people said this week, declining to be identified because the discussions are private.

JLL Partners declined to comment. Jefferies and BioClinica did not immediately respond to requests for comment.

The sale process highlights a wave of dealmaking activity that has overtaken the pharmaceutical services sector in recent months, with some of the largest players, including InVentiv Health Inc and Capsugel Inc, exploring an outright sale or an initial public offering, according to reports by Reuters.

Last year, another JLL Partners investment, Patheon, announced plans for an IPO. It is one of the largest contract manufacturing companies in the pharmaceutical industry.

In 2013, JLL Partners acquired BioClinica, which was at the time a publicly traded company, for an equity value of $123 million.

In the ensuing years, the buyout firm rapidly scaled up BioClinica through a series of acquisitions, including most recently with the purchase of specialty clinical trial services firm Synowledge.

BioClinica’s profits have grown as a result, with annual earnings before interest, taxes depreciation and amortization now approaching $100 million, according to the sources.

BioClinica assists pharmaceutical companies in clinical trials, and has expertise in technologies that focus on clinical research data and analytics. It supports over 17,000 clinical trial sites in 90 countries.

By Carl O’Donnell

Source: Reuters

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.